ODE II Director Jenkins Assumes Acting Title As Head Of E&M
Executive Summary
FDA Office of Drug Evaluation II Director John Jenkins, MD, is serving as acting director of FDA's Endocrine & Metabolic Drug Products Division following the departure Solomon Sobel, MD, to the Office of Review Management.